Edesa Biotech is trading 5.3% up at $7.17 in pre-market, extending its rebound from the July 13 close of $6.81.
- The upward move follows continued positive sentiment regarding recent Phase 3 paridiprubart data and a $3.5 million PIPE financing led by the CEO and healthcare-focused investors.
- The combination of clinical milestones and new capital has driven strong gains and bullish analyst coverage for the company in recent trading sessions.